Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Identifying novel hypoxia-associated markers of chemoresistance in ovarian cancer

Fig. 1

Hypoxia matrix treatment pathway. In the pre-treatment phase, cells received no, acute or chronic hypoxia. During treatment, cells that had prior hypoxia exposure were either treated in normoxia or hypoxia. Cells that had no prior hypoxia exposure were treated in normoxia for the full 3-day treatment period or in hypoxia for 1, 2 or 3 days, with any remaining treatment time in normoxia

Back to article page
\